Analgesic Treatment Mediated by Arcoxia (0663-093)

Analgesic Treatment Mediated by Arcoxia

Allow physicians to test the efficacy of arcoxia in patients with acute pain.

Study Overview

• Status: Completed
• Conditions: Pain
• Intervention / Treatment: Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

• Study Type: Interventional
• Enrollment (Anticipated): 237
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of acute pain susceptible of pharmacological treatment
• Greater than 18 years of age
• Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria:

• Allergy to etoricoxib or any of its components
• Less than 18 years old
• Patient is taking anticoagulants
• Patient that already has taken any drug as analgesic

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)

Secondary Outcome Measures

Outcome Measure
Patient satisfaction with the drug therapy using PGART scale
Patient satisfaction was obtained at the end of treatment(on third day)

Collaborators and Investigators

• Sponsor: Organon and Co

Study record dates

Study Major Dates

• Study Start: April 1, 2005
• Primary Completion (Actual): May 1, 2005
• Study Completion (Actual): May 1, 2005

Study Registration Dates

• First Submitted: September 22, 2006
• First Submitted That Met QC Criteria: September 22, 2006
• First Posted (Estimate): September 26, 2006

Study Record Updates

• Last Update Posted (Actual): February 16, 2022
• Last Update Submitted That Met QC Criteria: February 4, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Cyclooxygenase 2 Inhibitors; Etoricoxib
• Other Study ID Numbers: 0663-093; 2006_034